Major Advances in Gynaecological Cancers 2021

Webinar description

The webinar has been cancelled. We apologize for any inconvenience.

The special live ESGO webinar on July 8, 2021, is designed to offer an overview of the primary clinical trials results on both surgical and medical treatments, and highlight the most significant advances expected in future treatment approaches of gynaecological cancers.

This exclusive webinar will discuss the related key findings and results of selected significant surgical and medical treatment studies presented at conferences this year.

Learning objectives

To get acquainted to the results of major clinical trials and implication of these results in the clinical practice.

Target audience

Gynae-oncologists, medical oncologists, radiation oncologist

Scientific Program

18.30-18.35 Welcome & Opening

18.35-19.00 Improving the Standard of Care: More is NOT Better!

Mansoor Raza Mirza, Denmark

The OUTBACK Trial / ANZGOG 0902: Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone.

ENGOT-OV15 / AGO-OVAR 17: Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group.

Immunotherapy: New Era in the Management of Endometrial and Cervical Cancers

Mansoor Raza Mirza, Denmark

Keynote-775: A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer.

EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9: Interim analysis of phase 3 trial of cemiplimab vs investigator’s choice (IC) chemotherapy (CHEMO) in recurrent/ metastatic (R/M) carcinoma

19.00-19.20 Distillation of SGO 2021 Surgical Practice Abstracts

Nadeem Abu Rustum, USA

19.20-19.30 Q&A